Is it novel to select a numeric range overlapping with a previously
disclosed numeric range? A recent Court of Appeal judgment clarifies the UK approach to the patentability of numeric ranges.
According to UK case law and the Technical Boards of
Appeal (TBA) of the European Patent Office (EPO), for a range overlapping with a known range to be novel, the prior art must at least not disclose specific
values within the overlapping range. This is the principle that a generic disclosure is
not novelty destroying for specific examples covered by the generic.
|
An example outside the overlap does not destroy the novelty of an overlapping range |
The TBA
have established further criteria for an overlapping range to be novel. The claimed range must also, for example, have a technical effect. These criteria can seem addressed to the question of inventiveness as opposed to novelty. For this reason, the UK courts have previously been reluctant to adopt the TBA approach. The recent decision by
the Court of Appeal has now firmly incorporated part of the EPO's approach into UK case law.
The Patent
The case concerned whether OVC’s EP(UK) patent for glass fibres
(EP
1831118) was novel and inventive in view of a single piece of prior art. The Claimant, a Chinese fibreglass
manufacturer, admitted threatened infringement and brought an action of revocation against OVC's patent.
The patent relates to glass reinforcement strands that are
both cheap and easy to work with. Claim 1 specifies a glass strand composed of
a number of constituents at percentage weights within specified
ranges.
|
Fibreglass Kats |
The prior art US 4199364, “Neely”, was
cited by the patent itself. Neely
discloses glass compositions composed of the same compounds as that of the
patent, at the same or overlapping percentage weights. The point of contention in both the IPEC and
Court of Appeal was whether ranges in the prior art that overlapped with those of the invention were novelty destroying.
Novelty of
overlapping ranges – EPO approach
The EPO treats overlapping ranges as equivalent to sub-ranges
selected from a broader range of the prior art (T 666/89). In T 279/89 the TBA defined the
criteria by which overlapping ranges are assessed for novelty. The overlapping
range must be narrower and sufficiently removed from the end-points of
the known range. The selection must also have a technical effect, or in other
words, be another invention. This approach has been confirmed in subsequent
decisions by the TBA, and is currently supported by the EPO Guidelines for Examination.
T 230/07 contradicts the approach of T 279/89, and states that the present or absence of a technical effect of a selection
should not be taken into account when assessing novelty. According to the Board, such an assessment relates to the
inventiveness, not novelty, of the invention. However, this approach is not currently
supported by the guidelines.
According to the TBA, an overlapping range is also disclosed by the prior art if a skilled person would be able and reasonably expected to operate within the
overlap (T 26/85). In other words, an overlapping range is not novel if a skilled person
would have “seriously contemplated” operating within it. The TBA has emphasised
that this criteria is different
to the test for determining inventive step (T 666/89). In particular, the test for inventive step asks
whether a skilled person would have tried to bridge the technical gap between
the prior art and the claimed range, with a reasonable expectation of success. The
test for inventive step does not apply in the case of overlapping ranges
because there is no technical gap to bridge.
Novelty of
overlapping ranges – UK approach
The UK courts have previously expressed dissatisfaction with
the EPO’s approach to the novelty of overlapping ranges. In Lundbeck v Infosint [2011] EWHC 907 (Pat) (IPKat post
here), Mr Justice
Floyd observed in obiter that, according to the principles
of novelty adopted in the UK courts, an overlapping range is novel
solely on the basis that it is a narrower selection. This appeared to contradict the position of the TBA, which requires the additional criteria that the overlapping range would not be seriously contemplated in view of the
prior art range, and that selection of the range should have a technical
effect.
Jushi v OCV – The IPEC decision
At first instance, His Honour Judge Hacon reasoned that the “seriously contemplated” test of the TBA was in fact necessary to
determine the novelty of overlapping ranges. Hacon HHJ reasoned that under Floyd LJ's suggested approach,
ranges with 99% overlap with a known range would be novel. Hacon HHJ argued that the
TBA devised the “seriously contemplated” test to exclude such ranges.
This Kat is not convinced by this reading of the motives of the TBA. An overlapping range is treated as equivalent to a sub-range by the
EPO, and must therefore be sufficiently narrow compared to the known range (T
0666/89). According to the EPO Guidelines for Examination, the meaning of the term “narrow” is
to be assessed on a case-by-case basis. Thus, one might expect a range with 99%
overlap to lack novelty because it lacks narrowness, without the
need to assess whether the range would be seriously contemplated. The EPO’s criteria instead seem to be directed at removing
arbitrary selections from patentability, and subsets of the
prior art ranges that would have been readily used by the skilled person.
The Jushi v OCV dispute was
complicated by the multiple overlapping ranges specified in the claim. What was the overall percentage overlap over the entire claim with the prior art composition?
The Claimant’s expert put the total overlap at 3.9%, by multiplying
the individual percentages. The Defendant’s expert argued that this approach
was flawed, because it presumed that the individual overlapping ranges were
entirely independent: “Even at the simplest level, an increase in one constituent
could exert a downward pressure on the percentage of another, because the total
must always come to 100%”. Hacon HHJ was unable to determine the percentage overlap
from this testimony.
|
Overall percentage overlap? |
Hacon HHJ further remained unsure whether a skilled
person would seriously contemplate the overlapping range:
“I was in the end left with no
useful idea, not even a vague one, as how likely it was that the skilled person
would seriously contemplate juggling all 13 ranges in such a way as to arrive at
something within claim 1 of the Patent”
Hacon HHJ thus ruled that claim 1 was novel, given that he determined the burden of
proof to be on the side of the party alleging invalidity.
As an aside, this Kat’s own statistical expert advises her that the 3.9% figure for the overlapping ranges will be very close to
the true value. This is because there is only a single constraint (i.e on the sum of the constituents). The true figure isn't going to be lower than 3% or higher than 5%. The statistics required
to calculate the precise value are not as simple as multiplying the numbers together, but the value can easily be obtained by writing a straightforward computer program.
The Court of
Appeal
The Court of Appeal did not resolve the question of the amount
of overlap, but came to a finding of novelty for different reasons.
Applying the TBA approach, Lord Justice Floyd argued that a
skilled person would expect small changes in percentages to have large
non-linear effects on the properties of glass fibres. A skilled person would therefore not understand Neely as suggesting that one may indiscriminately choose
any
combination of values from the disclosed ranges. This analysis appears in line with the TBA approach, for which teaching away in the
prior art conferred novelty to an overlapping
range, because it demonstrates that a skilled person would not have seriously contemplated operating within the overlap (T 0026/85).
Lord Justice Floyd did not, however, follow the TBA approach
of additionally assessing whether the overlapping range has a technical effect. This was perhaps because the technical effect was assumed to be clear (given that the patent directly compared the invention with the glass fibres disclosed by Neely). However, there was perhaps scope for argument that the proposed technical effect was not enabled across the entire scope of the claim, and so could not confer an inventive step, at least according to a European approach to inventiveness.
Inventive step
The claims were also deemed inventive by both the IPEC and the Court of Appeal. In the Court of Appeal, Lord Justice Floyd employed similar reasoning as that used for novelty. Particularly, he reasoned that a skilled person would not be motivated to modify the ranges of Neely, given expert testimony that a skilled person would expect even small changes
to the individual constituents to have a disproportionately large effect on the properties of the
glass.
Commentary
The IPEC and Court of Appeal judgment clarify the UK court’s position on overlapping ranges. The UK’s approach is now in line
with that of the TBA, at least with regards to the test for the disclosure of an overlapping range in the prior art. To be novel, an overlapping range should not have been seriously contemplated by a skilled person in view of the prior art. However, neither court commented on whether
the EPO’s requirement that an overlapping range should have a technical effect
is consistent with the UK novelty requirement established by Lord Hoffmann
in Synthon BV v Smithkline Beecham plc [2005] UKHL 59. Given that the technical effect criteria is now the well-established approach of the TBA, it is hoped the UK courts will follow suit. But will this sit comfortably with the UK court's understanding of novelty? Jushi v OCV thus provides some clarity on the UK approach to the novelty overlapping ranges, but more is still needed.
Author: Rose Hughes
On numerous occasions, EPO decisions have (usually when UK practitioners have argued on the basis of EPO case law) stated that, unlike Anglo-Saxon jurisprudence, the instances of the EPO are not bound by precedent case law, but only by the provisions of the EPC. Therefore there appears to be no good reason why the UK courts should feel obliged to follow EPO case law when such case law does not bind the EPO itself.
ReplyDeleteFor me, this is a fine example of different jurisdictions helping each other to feel their way forward under the substantive provisions of patentability/novelty of the EPC. I like it, when the jurisprudence of English law, and that of the Boards of Appeal, converges, despite the gulf of difference between them in how they assess evidence of fact.
ReplyDeleteIt seems to me that, because of rivalry between EPC jurisdictions, progress under the EPC is almost Darwinian, survival of the fittest legal logic. Keeping novelty distinct from obviousness is easier said than done but here again, Europe leads the way, thanks to the EPC, Art 54(3).
Where else in the world, outside Europe, is there so much legal certainty, what is patentably novel, and what is not? Why, in the USA, they seem not yet to have got as far as considering elementary quesations about novelty, like whether D1 is to be construed as of its date of publication, or as of the day before the date of the claim.
Bravo, Floyd, LJ.
MaxDrei
ReplyDeleteI fear in the UK v EPO rivalry the EPO is dominant with the UK grudgingly following. I am sure the EPO will seldom pay any attention to UK decisions, and so in that sense it is more a Master-Slave dialectic (https://en.wikipedia.org/wiki/Master%E2%80%93slave_dialectic) or worse.
Whilst UK decisions are interestingly written, they have less and less influence in a world where rising to the top of one's regional power block is more important than one's ingenuity.